This article looks at what a transition to propellants with lower Global Warming Potential will involve and the lessons that can be learned from the industry’s earlier transition from CFCs to HFAs. Key issues that need to be addressed as formulators learn to work with propellants such as HFA 152a and HFO 1234ze include solubility of the active, the profile of the emitted spray, droplet size and evaporation, and electrostatic characteristics.
Aptar Pharma offers a comprehensive suite of services for those looking to accelerate their transition to low carbon MDIs including the Nanopharm SmartTrack™ platform which provides a wealth of information for formulation optimization.
Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery
This Might Also Be of Interest
Advancing Inhaled & Nasal Drug Clinical Studies: Insights & Strategies
Webinars, Pharmaceutical, Drug Delivery Innovations, Market Insights, Product Solutions
Leachables Assessment: New pMDI with Low-GWP Propellants
Publications, Pharmaceutical, Product Solutions, Sustainability, Drug Delivery Innovations, Brand Differentiation, Market Insights
Performance of Low-GWP Propellants in pMDIs: Filling and Dose Evaluation
Publications, Pharmaceutical, Sustainability, Drug Delivery Innovations, Market Insights, Product Solutions
Orally Inhaled Drug products; Bioequivalence Models
Publications, Pharmaceutical, Product Solutions, Drug Delivery Innovations, Brand Differentiation, Market Insights
